RESUMO
Only a few monoclonal antibodies (MAbs) have been isolated that recognize conserved sites in human immunodeficiency virus type 1 (HIV-1) Env proteins and possess broad neutralizing activities. Other MAbs directed against targets in various domains of Env have been described that are strongly neutralizing, but they possess limited breadth. One such MAb, 2909, possesses a uniquely potent neutralizing activity specific for a quaternary epitope on SF162 Env that requires the presence of both the V2 and the V3 domains. We now show that replacement of the SF162 V3 sequence with consensus V3 sequences of multiple subtypes led to attenuated but still potent neutralization by 2909 and that the main determinants for the type specificity of 2909 reside in the V2 domain. A substitution at position 160 completely eliminated 2909 reactivity, and mutations at position 167 either attenuated or potentiated neutralization by this antibody. Different substitutions at the same positions in V2 were previously shown to introduce epitopes recognized by MAbs 10/76b and C108g and to allow potent neutralization by these MAbs. Two substitutions at key positions in the V2 domain of JR-FL Env also allowed potent expression of the 2909 epitope, and single substitutions in YU2 V2 were sufficient for expression of the 2909, C108g, and 10/76b epitopes. These results demonstrate that the minimal epitopes for 2909, C108g, and 10/76b differed from that of the clade B consensus sequence only at single positions and suggest that all three MAbs recognize distinct variants of a relatively conserved sequence in V2 that is a particularly sensitive mediator of HIV-1 neutralization.
Assuntos
Anticorpos Monoclonais/imunologia , Especificidade de Anticorpos/imunologia , Proteína gp120 do Envelope de HIV/química , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Animais , Anticorpos Monoclonais/genética , Especificidade de Anticorpos/genética , Epitopos/química , Epitopos/genética , Anticorpos Anti-HIV , Proteína gp120 do Envelope de HIV/genética , HIV-1/genética , HIV-1/isolamento & purificação , Humanos , Testes de Neutralização , Pan troglodytes , Fragmentos de Peptídeos/metabolismo , Ligação Proteica , Precursores de Proteínas/metabolismo , Especificidade da EspécieRESUMO
The neutralizing activities of anti-V3 antibodies for HIV-1 isolates is affected both by sequence variation within V3 and by epitope masking by the V1/V2 domain. To analyze the relative contribution of V3 sequence variation, chimeric Env genes that contained consensus V3 sequences from seven HIV-1 subtypes in the neutralization-sensitive SF162 Env backbone were constructed. Resulting viral pseudotypes were tested for neutralization by 15 anti-V3 MAbs isolated from humans infected with viruses of either subtype B (anti-V3(B) MAbs) or subtype A (anti-V3(A) MAbs). Pseudovirions with the subtype B consensus V3 sequence were potently neutralized (IC(50) < 0.006 microg/ml) by all but one of these MAbs, while pseudovirions with V3 subtypes A, C, F, H, AG, and AE were generally neutralized more effectively by anti-V3(A) MAbs than by anti-V3(B) MAbs. A V1/V2-masked Env version of SF162 Env with the consensus B V3 sequence was also neutralized by these MAbs, although with considerably lower potency, while similarly masked chimeras with V3 sequences of subtype A, C, or AG were weakly neutralized by anti-V3(A) MAbs but not by anti-V3(B) MAbs. Mutations in the V1/V2 domain of YU-2 Env increased the sensitivity of this highly resistant Env to a pool of anti-V3(B) MAbs several thousand-fold. These results demonstrated (i) the exceptional sensitivity of representative V3 domains of multiple subtypes to neutralization in the absence of epitope masking, (ii) the broader neutralizing activity of anti-V3(A) MAbs for viruses containing diverse V3 sequences, and (iii) the generality and dominant effect of V1/V2 masking on restriction of V3-mediated neutralization.
Assuntos
Anticorpos Monoclonais/imunologia , Anticorpos Antivirais/imunologia , Especificidade de Anticorpos/imunologia , Epitopos/imunologia , Produtos do Gene env/imunologia , HIV-1/imunologia , Anticorpos Monoclonais/genética , Anticorpos Antivirais/genética , Especificidade de Anticorpos/genética , Epitopos/genética , Feminino , Produtos do Gene env/genética , HIV-1/genética , Humanos , Masculino , Mutação , Estrutura Terciária de Proteína/genética , Especificidade da Espécie , Vírion/genética , Vírion/imunologiaRESUMO
Although many human sera possess potent neutralizing activities for primary HIV-1 viruses, such activities are not efficiently induced by the current generation of vaccine candidates, and the epitopes mediating this neutralization are not known. The V3 loop of gp120 is believed to be the principal neutralization domain of laboratory-adapted viruses, but the importance of this region in neutralization of primary isolates is unclear. This question was explored using polyclonal anti-V3 antibodies purified by immunoaffinity methods from sera of HIV-1-infected patients. To include antibodies that might be directed against conformational and/or glycan-dependent epitopes not presented by synthetic peptides, the antibody isolations were performed with a fusion glycoprotein expressing the native V3 region of JR-CSF, a primary R5 isolate. V3-reactive antibody fractions from all eight sera examined showed potent neutralization of at least one of the three primary HIV-1 isolates tested; four of these antibody preparations neutralized all three primary viruses. For a number of serum-virus combinations 90% neutralization doses (ND(90)) between 1 and 5 microg/ml were obtained, and the most potent anti-V3 fraction had ND(50) values at or below 0.3 microg/ml for all three primary isolates. These neutralization activities against primary viruses were higher than those of potent monoclonal antibodies assayed in the same experiment. These data indicate that the V3 region can be an important neutralization target in primary isolates, and suggest that effective presentation of V3 epitopes in a vaccine formulation might induce protective humoral responses against natural infection by HIV-1.
Assuntos
Anticorpos Anti-HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Fragmentos de Peptídeos/imunologia , Sequência de Aminoácidos , Cromatografia de Afinidade , Glicosilação , Anticorpos Anti-HIV/sangue , Anticorpos Anti-HIV/isolamento & purificação , Proteína gp120 do Envelope de HIV/química , Humanos , Dados de Sequência Molecular , Testes de Neutralização , Fragmentos de Peptídeos/química , Homologia de Sequência de AminoácidosRESUMO
Although it is known that some human immune sera possess potent neutralizing activities for primary viruses, the identity of the target epitopes mediating this neutralization is unknown, and currently available immunogens have not been able to induce such activities. Using recombinant fusion glycoproteins expressing native V1/V2 domains of gp120 we have found that sera from a subset of HIV-1-infected humans contain antibodies that recognize broadly conserved V1/V2 epitopes. Such antibodies were isolated from one human serum by affinity chromatography on a column containing a V1/V2 fusion protein, and shown to efficiently neutralize several macrophage-tropic HIV-1 isolates. Rodents immunized with the purified V1/V2 fusion protein produced antibodies reactive with unrelated V1/V2 fusion proteins and with heterologous gp120s. V1/V2-specific immunoglobulins isolated from sera of these animals by affinity chromatography also possessed potent neutralization activity for several primary HIV-1 isolates. These results indicate that the V1/V2 domain of HIV-1 gp120 contains conserved epitopes that mediate potent neutralization of primary viruses, and suggest that subunit vaccines that efficiently induce such antibodies may provide protective humoral immunity against clinically relevant HIV-1 isolates.
Assuntos
Epitopos/imunologia , Anticorpos Anti-HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Sequência de Aminoácidos , Animais , Anticorpos Monoclonais/imunologia , Especificidade de Anticorpos , Células CHO/metabolismo , Cromatografia de Afinidade , Cricetinae , Anticorpos Anti-HIV/sangue , Infecções por HIV/sangue , Infecções por HIV/imunologia , Humanos , Dados de Sequência Molecular , Testes de Neutralização , Fenótipo , Estrutura Terciária de Proteína , Proteínas Recombinantes de Fusão/imunologiaRESUMO
Synergistic neutralization of human immunodeficiency virus type 1 (HIV-1) was observed in studies using a chimpanzee anti-V2 monoclonal antibody (MAb), C108G, in combination with anti-V3 loop and anti-CD4 binding-site (bs) MAbs of different epitope specificities. C108G paired with either of two anti-V3 loop MAbs or either of two anti-CD4 bs MAbs synergistically neutralized both the uncloned IIIB and clonal HXB2 strains of virus in H9 target cells. Synergism was quantitated by calculation of combination indices. Significant synergy with a given MAb pair was seen over a range of MAb ratios, with the optimal effect centering around the ratio at which the MAbs were equipotent for a given HIV-1 strain (on the basis of the 50% neutralization titer). In preliminary experiments with monocytotropic strains of HIV-1 in peripheral blood mononuclear cell targets, significant synergism was also observed between anti-V2-anti-V3 and anti-V2-anti-CD4 bs MAb pairs. Synergism by all MAb pairs tested was greater against heterogeneous isolates of HIV-1 (IIIB and Ba-L) than against clonal isolates (HXB2 and NLHXADA), suggesting that strain broadening may be a component of the synergism observed against the heterogeneous isolates. In addition, conformational changes in gp120 upon binding of one or both MAbs may result in increased affinity or exposure of the epitope of one or both MAbs. Finally, a three-MAb combination of C108G, an anti-V3 MAb, and an anti-CD4 bs MAb was more effective in neutralizing the HXB2 strain of HIV-1 than any of the three two-MAb combinations within this trio, as determined by the dose reduction indices of each MAb required to achieve a given level of neutralization. This is the first report of synergistic neutralization of HIV-1 by a three-MAb combination composed of MAbs directed against the three major neutralization epitope clusters in gp120. Implications for vaccine design and for immunoprophylaxis and immunotherapy with a combination of MAbs are discussed.
Assuntos
Anticorpos Monoclonais/imunologia , Antígenos CD4/imunologia , Anticorpos Anti-HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Fragmentos de Peptídeos/imunologia , Animais , Humanos , Testes de Neutralização , Pan troglodytes , Células Tumorais CultivadasRESUMO
An anti-gp120 monoclonal antibody (MAb), C108G (gamma 1, kappa), was isolated from a chimpanzee that had been infected with strain IIIB of human immunodeficiency virus type 1 (HIV-1IIIB) and subsequently immunized with the recombinant glycoprotein rgp160MN. This MAb is specific for the IIIB strain of HIV-1 and related clones and exhibits very potent neutralization of these viruses; e.g., 100% neutralization of approximately 8 x 10(3) infectious units of HXB2 was achieved with 125 ng of C108G per ml. Commensurate with this potent neutralizing activity, the apparent affinity of C108G for rgp160LAI was very high, i.e., approximately 3 x 10(10) liters/mol. The C108G epitope was not destroyed by reduction of gp120 disulfide bonds but was profoundly disrupted by removal of N-linked sugars from gp120. Despite the importance of a glycan(s) in forming the C108G epitope, specific binding of C108G to synthetic peptides overlapping in amino acids 162 to 169 of the V2 region was detected, albeit with an affinity approximately 2,000-fold lower than that of C108G's binding to glycosylated envelope protein. This epitope mapping correlated with results of competition assays using MAbs of known epitope specificities. To our knowledge, this is the first description of an anti-V2 MAb raised in response to HIV-1 infection. Its potent neutralizing activity and epitope specificity indicate that the V2 domain of gp120 may be an effective target of the protective immune response and, therefore, potentially an important component of HIV vaccines.
Assuntos
Anticorpos Monoclonais/imunologia , Epitopos/imunologia , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Sequência de Aminoácidos , Animais , Anticorpos Monoclonais/isolamento & purificação , Western Blotting , Ensaio de Imunoadsorção Enzimática , Dados de Sequência Molecular , Testes de Neutralização , Pan troglodytes , PolissacarídeosRESUMO
A human monoclonal antibody (HuMAb), 5145A, against HIV-1 gp120 was isolated from an asymptomatic, seropositive hemophiliac. The epitope of this HuMAb was destroyed by reduction of gp120 disulfide bonds, but not by removal of N-linked carbohydrates. This epitope overlaps the CD4-binding site of gp120, because binding of 5145A to gp120 is inhibited by soluble CD4 and by 1125H, a previously described HuMAb directed toward the CD4-binding site. However, the 5145A epitope differs from those of 1125H and other anti-CD4-binding site HuMAbs previously described, as documented by the viral strain specificity of 5145A and its reactivity with a panel of gp120 mutants. Specifically, 5145A reacted with 14 of 15 HIV-1 isolates tested, including 9 isolates from the Central African Republic, 6 of which were not recognized by 1125H. Partial epitope mapping of 5145A, using a series of gp120 mutants, demonstrated its lack of sensitivity to mutations in residues 257 and 427, contrasting with a marked sensitivity to mutations in residues 368 and 370. This pattern of reactivity distinguishes its epitope from that of any HuMAb against the CD4-binding site region described to date. In addition, 5145A exhibited potent and essentially equivalent neutralization of the MN, SF-2, IIIB, and RF strains and possessed significant neutralizing activity against three of three African strains tested. Finally, 5145A synergistically neutralized the MN and SF-2 strains of HIV-1 when combined with 4117C, a HuMAb against the V3 loop. The broad strain specificity and potent neutralizing activity of 5145A, together with its ability to synergize with an anti-V3 loop HuMAb in neutralizing HIV-1, indicate that 5145A has excellent potential as a passive immunotherapeutic agent against HIV-1.
Assuntos
Anticorpos Monoclonais/imunologia , Antígenos CD4/imunologia , Epitopos/imunologia , Anticorpos Anti-HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Síndrome da Imunodeficiência Adquirida/epidemiologia , Sítios de Ligação de Anticorpos , Ligação Competitiva , Western Blotting , República Centro-Africana/epidemiologia , Reações Cruzadas , Ensaio de Imunoadsorção Enzimática , Produtos do Gene env/imunologia , HIV-1/isolamento & purificação , Humanos , Testes de Neutralização , América do Norte/epidemiologiaRESUMO
Two neutralizing human monoclonal antibodies (HuMAbs) directed against epitopes located near the tip of the V3 loop of human immunodeficiency virus type 1 env protein recognized solubilized gPr160, but not gp120, in radioimmunoprecipitation assays. Efficient immunoprecipitation of solubilized gp120 by these antibodies did occur in the presence of HuMAb 1125H, directed against a conformational epitope overlapping the CD4-binding site, or its F(ab')2 fragment. In contrast to the inability of the anti-V3 antibodies to immunoprecipitate solubilized gp120, these HuMAbs did bind to gp120 in intact virions; this level of binding increased severalfold in the presence of the F(ab')2 fragment of 1125H. These results demonstrate that neutralization epitopes in the V3 loop are sequestered in soluble gp120 but partly exposed in gPr160 and in virion-associated gp120 and that binding of antibodies to the discontinuous CD4-binding site leads to conformational changes that result in the exposure of V3 epitopes in soluble gp120 and their enhanced accessibility in gPr160 and in virion-associated gp120. Enhanced binding of suboptimal concentrations of 1125H to soluble gp120 was also induced by the presence of an anti-V3 HuMAb, indicating the occurrence of reciprocal allosteric interactions between the V3 loop and the CD4-binding site. It is likely that these effects contribute to the synergistic neutralization of human immunodeficiency virus type 1 previously reported for antibodies directed against these two regions.
Assuntos
Antígenos CD4/metabolismo , Genes env , Proteína gp120 do Envelope de HIV/química , Proteína gp120 do Envelope de HIV/metabolismo , HIV-1/metabolismo , Conformação Proteica , Sequência de Aminoácidos , Anticorpos Monoclonais , Sítios de Ligação , Sequência Conservada , Epitopos/química , Epitopos/metabolismo , Produtos do Gene env/química , Produtos do Gene env/metabolismo , Proteína gp160 do Envelope de HIV , Humanos , Ligantes , Dados de Sequência Molecular , Precursores de Proteínas/química , Precursores de Proteínas/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Vírion/metabolismoAssuntos
Anticorpos Monoclonais/imunologia , Produtos do Gene gag/imunologia , Glicoproteínas/imunologia , Anticorpos Anti-HIV/imunologia , Antígenos HIV/imunologia , HIV-1/imunologia , Proteínas Virais , Animais , Especificidade de Anticorpos , Glicosilação , Humanos , Soros Imunes , Pan troglodytes/imunologia , Ratos , Produtos do Gene gag do Vírus da Imunodeficiência HumanaRESUMO
Two distinct regions or epitope clusters of human immunodeficiency virus type 1 (HIV-1) gp120 have been shown to elicit neutralizing antibodies: the V3 loop and the CD4-binding site. We have isolated neutralizing human monoclonal antibodies (HuMAbs) against conserved epitopes in both of these regions. In this study, we demonstrate that an equimolar mixture of two of these HuMAbs, one directed against the V3 loop and the other against the CD4-binding site, neutralizes HIV-1 at much lower concentrations than does either of the individual HuMAbs. Mathematical analysis of this effect suggests cooperative neutralization of HIV-1 by the two HuMAbs and demonstrates a high level of synergy, with combination indices (CIs) of 0.07 and 0.16 for 90% neutralization of the MN and SF-2 strains, respectively. The dose reduction indices (DRIs) for each of the two HuMAbs at 99% neutralization range approximately from 10 to 150. A possible mechanism for this synergism is suggested by binding studies with recombinant gp160 of the MN strain; these show enhanced binding of the anti-CD4 binding site HuMAb in the presence of the anti-V3 loop HuMAb. These results demonstrate the advantage of including both V3 loop and CD4-binding site epitopes in a vaccine against HIV-1 and indicate that combinations of HuMAbs against these two sites may be particularly effective in passive immunotherapy against the virus.
Assuntos
Anticorpos Monoclonais/imunologia , Antígenos CD4 , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Testes de Neutralização , Fragmentos de Peptídeos/imunologia , Sítios de Ligação , Linhagem Celular Transformada , Epitopos/imunologia , Humanos , Matemática , Modelos BiológicosRESUMO
A human monoclonal antibody (HuMAb) against HIV1, 1125H, was isolated from an asymptomatic, seropositive haemophiliac. This antibody was specific for gp120, and its binding to gp120 was inhibited by soluble CD4, indicating that its epitope was in or near the CD4-binding site. 1125H antibody recognized a variety of divergent HIV1 strains, including most laboratory strains tested as well as some early passage isolates. Commensurate with its specificity and high apparent affinity, 1125H exhibited potent neutralizing activity against IIIB, MN, RF and SF-2 strains. The epitope recognized by 1125H was destroyed by reduction of disulphide bonds, but not by removal of N-linked sugars. Thus, the epitope was conformationally determined and did not involve carbohydrate. Data from radioimmunoprecipitation/SDS-PAGE analysis of proteolytically cleaved viral lysate further indicated that the epitope of 1125H was not affected by cleavage at the V3 loop of gp120, provided that gp120 disulphide bonds remained intact. The potential use of HuMAb 1125H in passive immunotherapy against HIV is discussed as well as the importance of including its epitope in an AIDS vaccine.
Assuntos
Anticorpos Monoclonais/imunologia , Antígenos CD4/imunologia , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/imunologia , Especificidade de Anticorpos , Sítios de Ligação , Dissulfetos , Epitopos/imunologia , Soropositividade para HIV/imunologia , Hemofilia A/imunologia , Humanos , Testes de Neutralização , Sensibilidade e EspecificidadeRESUMO
The mature product of the env gene of Friend spleen focus-forming viruses (F-SFFV) is efficiently released from both leukemia cells and infected fibroblasts. Analyses of the kinetics of env protein synthesis and secretion in NRK cells infected with the Lilly-Steeves strain of SFFVp indicated that this product, gp65, was formed rapidly and remained stably associated with cells for up to 4 hr, at which point it was first detected in supernatant medium. By 12 hr after synthesis, greater than 95% of gp65 was found extracellularly. The release of this component was effectively blocked by 10 mM 1-deoxynojirimycin, an inhibitor of oligosaccharide processing, demonstrating a requirement for processing of high mannose precursor oligosaccharides in the secretion of gp65. Similar oligosaccharide substituents were found on cell-associated and extracellular forms of gp65. Enzymatic deglycosylation experiments demonstrated that in addition to the predicted four N-linked oligosaccharides, gp65 contains O-linked carbohydrates which are resistant to the action of peptide N-Glycanase F, but sensitive to neuraminidase and O-Glycanase. These structures may be related to O-linked oligosaccharides previously found on the env gene products of murine leukemia viruses. Comparison of the sizes of the deglycosylated forms of cell-associated and supernatant gp65 demonstrated that the extracellular molecules are approximately 3 kDa smaller than the cell-associated components. These data suggest the involvement of proteolysis at a C-terminal site in the release of gp65 from the plasma membrane.
Assuntos
Produtos do Gene env/metabolismo , Vírus da Leucemia Murina/genética , Processamento de Proteína Pós-Traducional , Vírus Formadores de Foco no Baço/genética , Membrana Celular/metabolismo , Células Clonais , Fibroblastos , Produtos do Gene env/análise , Produtos do Gene env/genética , Genes env , Glicosídeo Hidrolases/metabolismo , Cinética , Oligossacarídeos/análise , Ensaio de Radioimunoprecipitação , Vírus Formadores de Foco no Baço/metabolismo , Vírus Formadores de Foco no Baço/ultraestruturaRESUMO
We characterized the structural forms of the human immunodeficiency virus env-encoded proteins with a panel of monoclonal and polyclonal antibodies. Western blot (immunoblot) assays with antibodies specific for gp41 invariably recognized a major component of 160 kilodaltons and a less intense component of 120 kilodaltons in viral lysates. We demonstrated that these species are noncovalently associated tetramers and trimers of gp41 which represent the native form of this protein in virions. These complexes were stable when boiled in the presence of low concentrations of sodium dodecyl sulfate but were dissociated to gp41 monomers at high sodium dodecyl sulfate concentrations. Moreover, two human monoclonal antibodies preferentially recognized the oligomeric complexes over monomeric gp41 in Western blots, indicating the presence of epitopes recognized by the human immune system on the gp41 multimers which are not efficiently expressed by the dissociated monomers. The demonstration of the existence of multimeric env complexes and the enhanced and altered antigenicity of such multimers may be relevant to the design of subunit and recombinant human immunodeficiency virus env vaccines.
Assuntos
Antígenos HIV/análise , HIV-1/análise , Proteínas do Envelope Viral/análise , Anticorpos Monoclonais/imunologia , Anticorpos Antivirais/imunologia , Especificidade de Anticorpos , Western Blotting , Eletroforese em Gel Bidimensional , Eletroforese em Gel de Poliacrilamida , Antígenos HIV/imunologia , Proteína gp41 do Envelope de HIV , HIV-1/imunologia , Humanos , Testes de Precipitina , Kit de Reagentes para Diagnóstico , Proteínas do Envelope Viral/imunologiaRESUMO
A sensitive and efficient radioimmunoprecipitation procedure is described which provides an alternative to Western blotting assays for characterizing antibodies directed against human immunodeficiency viruses (HIV-1). Reaction of solubilized preparations of HTLV-III with 125I-labeled Bolton-Hunter reagent leads to the efficient labeling of all of the major virus-specific proteins, including gp120, gp41, RT (p66/p51), p24, and p17. These labeled proteins are readily immunoprecipitated by immune human sera, by specific sera derived from hyperimmunized animals, and by monoclonal antibodies. This procedure, referred to as BH-RIP, provides a simple assay for characterizing and titering antibodies against HIV which is equivalent in specificity, and more sensitive and efficient than the Western blotting method. In addition, viral proteins labeled in this way are suitable for biochemical studies. In one such application, the number of high-mannose and complex oligosaccharide side chains of gp120 and gp41 were determined by examining the sensitivities of the two viral glycoproteins labeled by this procedure to the glycosidases Endo H and PNGase F.
Assuntos
Soropositividade para HIV/diagnóstico , HIV/imunologia , Radioimunoensaio/métodos , Síndrome da Imunodeficiência Adquirida/microbiologia , Anticorpos Antivirais/análise , Especificidade de Anticorpos , Antígenos Virais/análise , Carboidratos/análise , Precipitação Química , Eletroforese em Gel de Poliacrilamida , Glicoproteínas/imunologia , Glicosídeo Hidrolases/metabolismo , Peso MolecularRESUMO
Treatment of [3H]glucosamine-labeled Friend mink cell focus-forming virus (FrMCF) gp70 with excess peptide:N-glycanase F (PNGase F) resulted in removal of the expected seven N-linked oligosaccharide chains; however, approximately 10% of the glucosamine label was retained in the resulting 49,000-Mr (49K) product. For [3H]mannose-labeled gp70, similar treatment led to removal of all the carbohydrate label from the protein. Prior digestion of the PNGase F-treated gp70 with neuraminidase resulted in an additional size shift, and treatment with O-glycanase led to the removal of almost all of the PNGase F-resistant sugars. These results indicate that gp70 possesses sialic acid-containing O-linked oligosaccharides. Analysis of intracellular env precursors demonstrated that O-linked sugars were present in gPr90env, the polyprotein intermediate which contains complex sugars, but not in the primary translation product, gPr80env, and proteolytic digestion studies allowed localization of the O-linked carbohydrates to a 10K region near the center of the gp70 molecule. Similar substituents were detected on the gp70s of ecotropic and xenotropic murine leukemia viruses and two subgroups of feline leukemia virus, indicating that O-linked glycosylation is a conserved feature of retroviral env proteins.
Assuntos
Glicoproteínas/biossíntese , Vírus da Leucemia Murina/metabolismo , Vírus Indutores de Focos em Células do Vison/metabolismo , Oligossacarídeos/metabolismo , Proteínas Oncogênicas de Retroviridae , Proteínas dos Retroviridae/biossíntese , Proteínas do Envelope Viral/biossíntese , Vírus da Leucemia Felina/genética , Vírus da Leucemia Felina/metabolismo , Vírus da Leucemia Murina/genética , Vírus Indutores de Focos em Células do Vison/genética , Precursores de Proteínas/metabolismo , Processamento de Proteína Pós-TraducionalRESUMO
The env genes of Friend spleen focus-forming viruses (F-SFFV) have been implicated in the rapid pathogenicity of these agents. Two env-gene products are detected in SFFV-infected cells: the primary translation product, gp52, and a more highly processed form, gp65. In this communication we demonstrate that gp65 is the major end product of the SFFV env gene, and is efficiently secreted from both erythroleukemia cells and infected fibroblasts. Secretion was observed for the mature env-gene products of both polycythemia- and anemia-inducing strains of SFFV. These results suggest that one function of the point mutation near the 3' end of the env gene, which is invariant in the formation of SFFVs, is to allow secretion of gp65, and that secreted gp65 may be the factor mediating the leukemogenic activity of these viruses.
Assuntos
Vírus da Leucemia Murina/genética , Vírus Formadores de Foco no Baço/genética , Proteínas do Envelope Viral/genética , Animais , Linhagem Celular , Genes Virais , Rim , Cinética , Leucemia Eritroblástica Aguda , Leucemia Experimental , Camundongos , Ratos , Proteínas do Envelope Viral/isolamento & purificação , Proteínas do Envelope Viral/metabolismoRESUMO
The functions of asparagine-linked oligosaccharides on the PrENV protein of Friend mink cell focus-inducing (FrMCF-1) murine leukemia virus were investigated by examining the effect of two inhibitors of different stages of the biosynthetic pathway of these sugar substituents on the synthesis and processing of the viral proteins. Treatment of virus-producing cells with tunicamycin totally inhibited the glycosylation of PrEnv, and resulted in the formation of a nonglycosylated form of the protein of molecular weight 62 kDa. This component was not proteolytically processed inside the cells, and neither it nor any derivative proteins were incorporated into extracellular virions. Treatment of cells with 1-deoxynojirimycin (DNM), which inhibits the cellular glucosidases normally involved in removal of the three glucose residues present on the initially transferred oligosaccharide chains, resulted in the intracellular accumulation of a slightly larger than normal form of PrENV, and decreased levels of cell-associated gp70. Only gp70 was detected on the cell surface. The bulk of the gp70 produced in the presence of the drug was aberrantly glycosylated, and contained decreased levels of complex and increased numbers of high mannose oligosaccharides; almost all of the gp70 molecules however, contained at least one complex sugar chain. Decreased incorporation of both env and gag proteins into extracellular virions was observed, despite the fact that the gag proteins were processed normally intracellularly; in contrast, DNM treatment of Gazdar murine sarcoma virus-infected HTG2 cells, which produce only gag but not env proteins, did not inhibit the release of extracellular virus. Ultrastructural examination of FrMCF-infected cells treated with DNM indicated the presence of large numbers of intracytoplasmic vacuoles, many of which contained viral particles. These studies indicate that the normal maturation process involved in the formation of complex oligosaccharides is necessary to obtain efficient transport to the plasma membrane and proteolysis of PrEnv, and also provide evidence suggesting a role for the env proteins in regulating assembly of gag proteins into virions.
Assuntos
Membrana Celular/metabolismo , Vírus da Leucemia Murina/metabolismo , Oligossacarídeos/fisiologia , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Proteínas do Envelope Viral/metabolismo , 1-Desoxinojirimicina , Animais , Transporte Biológico , Linhagem Celular , Membrana Celular/microbiologia , Glucosamina/análogos & derivados , Glucosamina/farmacologia , Vírus da Leucemia Murina/efeitos dos fármacos , Camundongos , Vison , Tunicamicina/farmacologia , Vírion/efeitos dos fármacos , Vírion/metabolismoRESUMO
A detailed comparison of the gp70 proteins of cloned ecotropic Friend murine leukemia virus (FLV) and dual-tropic Friend mink focus-forming virus (FrMCF) was performed by analyzing the structural and immunological properties of amino- and carboxy-terminal domains of these molecules generated upon controlled trypsinization. The two gp70s gave characteristic fragmentation patterns; the amino-terminal fragments of FrMCF gp70 were smaller than the corresponding fragments of FLV and contained a trypsin site which resulted in a 19,000-dalton amino-terminal fragment not observed for FLV, whereas both molecules yielded an identically sized carboxy-terminal fragment. All amino-terminal fragments of both gp70 molecules contained an endo H-sensitive oligosaccharide chain; for FrMCF, a second endo H-sensitive carbohydrate was present as well at a carboxy-terminal site for approximately 50% of the molecules. Several aspects of the disulfide interactions of the two gp70s were conserved; in both cases the carboxy-terminal fragments were disulfide bonded to p15(E), there were no disulfide bonds between amino- and carboxy-terminal fragments, and the amino-terminal fragments exhibited a significant increase in mobility upon analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions. Analysis of the immunoreactivity of the different domains of the proteins by immunoprecipitation of the fragments with antisera prepared against xenotropic murine leukemia virus and feline leukemia virus gp70s indicated major differences in antigenicity for the amino-terminal domains of FLV and FrMCF gp70, whereas the carboxy-terminal domains were immunologically conserved. Similar analyses with antibodies specific for p15(E) and Pr15(E) demonstrate that these components are conserved as well. These data provide direct evidence that p15(E) and the C-terminal gp70 domain of FrMCF gp70 are related to the corresponding regions of the ecotropic FLV parent and indicate that the acquisition of MCF-specific properties is due to the replacement of the ecotropic amino-terminal gp70 domain with sequences related to those of xenotropic gp70s.
Assuntos
Vírus da Leucemia Murina de Friend/genética , Genes Virais , Genes , Vírus da Leucemia Murina/genética , Proteínas do Envelope Viral/genética , Animais , Complexo Antígeno-Anticorpo , Células Cultivadas , Epitopos/análise , Camundongos , Peso Molecular , Fragmentos de Peptídeos/análise , Tripsina , Proteínas do Envelope Viral/imunologia , Proteínas do Envelope Viral/isolamento & purificaçãoRESUMO
Controlled proteolysis of MuLV gp70s results in the generation of several fragments which correspond to distinct structural domains of the molecules. The orientation of these regions in gp70 was determined by analysis of the immunoreactivities of proteolytic products generated from the MuLV PrENV polyprotein toward monoclonal alpha p15(E) and alpha gp70 antibodies, and by fragmentation analysis of gp70s specifically labeled with [35S]cysteine and [35S]methionine. These studies confirmed our previous assignment of a p15(E)-disulfide-linked 33K fragment to the carboxy terminus of Akv gp70 (Pinter, Honnen, Tung, O'Donnell, and Hammerling, Virology 116, 345-351, 1982). Using similar fragmentation procedures, the sizes and structural features of gp70 domains of Akv and MCF 247 MuLV gp70s were compared. Trypsinization of MCF-247 gp70 resulted in the production of a carboxy terminal fragment which resembled that of the ecotropic gp70 in that (1) it was disulfide linked to p15(E) but not to the amino terminal fragments, (2) reacted with monoclonal antibody 35/56, (3) contained cysteines but no methionines, and (4) carried only endo H-resistant oligosaccharide chains. Amino terminal MCF gp70 fragments were obtained with apparent molecular weights of 42K and 30K, considerably smaller than the corresponding Akv fragments of 49K and 35K. These MCF fragments were much more stable to degradation by trypsin than the Akv amino terminal components, indicating the loss or inaccessibility of several trypsin sites in the MCF amino terminal domain. These results demonstrated the Akv and MCF 247 gp70s contained highly conserved carboxy terminal domains but unique amino terminal sequences. Common features for both gp70s were the presence of an endo H-sensitive oligosaccharide chain near the amino terminus, and the presence of internal disulfide bonds in the amino terminal domains which resulted in an increased mobility for these fragments when analyzed under nonreducing conditions. Thus, while the amino terminal domains of the two gp70s are structurally different, certain aspects of glycosylation specificity and secondary conformation are conserved, suggesting that these structural features may be important for common biological properties of these molecules.